Peterson Mark R, Coop Christopher A
From the Department of Allergy and Immunology, Wilford Hall Abulatory Surgical Center, Lackland AFB, San Antonio, Texas.
Allergy Rhinol (Providence). 2017 Oct 1;8(3):170-172. doi: 10.2500/ar.2017.8.0204.
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed. He was refractory to these medications and continued to have episodes of EIA. He was then started on a trial of omalizumab, an immunoglobulin E monoclonal antibody, and had resolution of the EIA episodes. After discontinuation of the omalizumab, the EIA episodes returned. He was restarted on omalizumab and since that time, has had 5 years free of EIA episodes and can now exercise without any symptoms. To our knowledge, this is only the third case in the literature of successful treatment of EIA by using omalizumab. This case was unique because it provided successful long-term use of omalizumab for EIA. Further studies are recommended for the use of omalizumab in the treatment of EIA.
报告了一例39岁男性被诊断为运动诱发性过敏反应（EIA）的病例。他最初接受非索非那定、孟鲁司特和雷尼替丁预防性治疗。他还根据需要使用肾上腺素自动注射器。他对这些药物难治，EIA发作仍持续。然后他开始试用奥马珠单抗，一种免疫球蛋白E单克隆抗体，EIA发作得到缓解。停用奥马珠单抗后，EIA发作又复发。他重新开始使用奥马珠单抗，从那时起，已经有5年没有EIA发作，现在可以运动且没有任何症状。据我们所知，这是文献中第三例使用奥马珠单抗成功治疗EIA的病例。该病例独特之处在于它实现了奥马珠单抗对EIA的长期成功使用。建议对奥马珠单抗在EIA治疗中的应用进行进一步研究。
